ORION CORPORATION STOCK EXCHANGE RELEASE 20 JAN 2012 AT 9.30 EET
In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2011. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/sereleases (http://www.orion.fi/sereleases).
Orion points out that part of the information in the releases can have become out-dated.
Stock Exchange Releases in 2011
| January | |
| Jan 14th 2011 | 79,866 Orion A-shares converted into B-shares |
| Jan 19th 2011 | Annual Summary of Stock Exchange Releases published in 2010 |
| Jan 20th 2011 | Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011 |
| Jan 24th 2011 | Orion sues Mylan in the U.S. to enforce its U.S. patent covering the proprietary drug Comtan® |
| Jan 31st 2011 | Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2011 AGM of Orion Corporation |
| February | |
| Feb 9th 2011 | Orion Group Financial Statement Release for 2010 |
| Feb 9th 2011 | Notice to the Annual General Meeting of Orion Corporation |
| March | |
| Mar 1st 2011 | Orion Corporation: Transfer of 102,900 own B-shares |
| Mar 9th 2011 | Orion Group Annual Report 2010 published |
| Mar 31st 2011 | President and CEO Timo Lappalainen today at Annual General Meeting of Orion Corporation: Orion's sales developed well in early 2011 |
| Mar 31st 2011 | Orion Corporation: Decisions by the AGM on 31 March 2011 |
| Mar 31st 2011 | Orion Corporation: Organising meeting of the Board of Directors |
| April | |
| Apr 13th 2011 | Orion upgrades full-year outlook for 2011 |
| Apr 18th 2011 | Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011 |
| Apr 20th 2011 | 397,408 Orion A-shares converted into B-shares |
| Apr 27th 2011 | Orion Group Interim Report January-March 2011 |
| May | |
| May 5th 2011 | 173,500 Orion A-shares converted into B-shares |
| June | |
| Jun 9th 2011 | 628,914 Orion A-shares converted into B-shares |
| Jun 22nd 2011 | 100,000 Orion A-shares converted into B-shares |
| July | |
| Jul 18th 2011 | Orion invites analysts and media to Q2 news conference on Tuesday 2 August 2011 |
| Jul 22nd 2011 | Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine) |
| August | |
| Aug 2nd 2011 | Orion Corporation's publication schedules for financial reporting in 2012 |
| Aug 2nd 2011 | Orion Group Interim Report January-June 2011 |
| Aug 19th 2011 | 136,231 Orion A-shares converted into B-shares |
| September | |
| Sep 14th 2011 | 400,000 Orion A-shares converted into B-shares |
| Sep 21st 2011 | Orion receives European marketing authorisation for dexdor® |
| Sep 21st 2011 | Composition of the Nomination Committee of Orion Corporation |
| Sep 23rd 2011 | 400,000 Orion A-shares converted into B-shares |
| Sep 26th 2011 | Disclosure Under Chapter 2 Section 10 |
| October | |
| Oct 11th 2011 | Orion invites analysts and media to Q3 news conference on Tuesday 25 October 2011 |
| Oct 25th 2011 | Orion Group Interim Report January-September 2011 |
| Oct 25th 2011 | Change in Orion Group Executive Management Board as of 1 January 2012 |
| November | |
| Nov 7th 2011 | 53,428 Orion A-shares converted into B-shares |
| Nov 7th 2011 | Disclosure Under Chapter 2 Section 10 |
| December | |
| Dec 20th 2011 | Orion Corporation: 201,000 Orion A-shares converted into B-shares |
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi (http://www.orion.fi/)
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
